ClinicalTrials.gg
CompletedNCT06354998Updated May 25, 2025Results posted

A Study of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated Adults

A Phase 3 interventional study of Investigational mRNA-1273.815 and Licensed Spikevax Vaccine in SARS-CoV-2, sponsored by ModernaTX, Inc.. Completed at 7 sites in Australia. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-25.

Primary conditionCOVID-19Registry: Coronavirus InfectionsReclassifiedWhy we changed it
Registry
Coronavirus Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
COVID-19
Why
  1. The study's title name COVID-19, a narrower term within Coronavirus Infections.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
217
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 34 studies in COVID-19 by Moderna, Inc. — 3 open to participants now, 6 under way, none of them phase 3. COVID-19 · Moderna, Inc..

Enrollment
20th of 22
217 · median 988
Started
2024
with 2 others
Phase 3
6 of 34
none open now
Registered
27th of 34
by date

Among the 34 studies in COVID-19 by Moderna, Inc., this one is the 20th largest by enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2024, is one of 6 in phase 3, and was the 27th registered.

COVID-19

7,993 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

3 of the 34 studies in COVID-19 by Moderna, Inc. are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in COVID-19 by Moderna, Inc., or all of them as a file.
02

Study summary

To evaluate immune responses of an Investigational mRNA-1273.815 vaccine against the Omicron subvariant strain (XBB.1.5) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

03

Conditions studied

  • SARS-CoV-2

Browse trials for

Keywords

  • mRNA-1273.815
  • mRNA-1273.815 vaccine
  • SARS-CoV-2
  • SARS-CoV-2 Vaccine
  • Coronavirus
  • Messenger RNA
  • COVID-19
  • COVID-19 Vaccine
  • Moderna
04

In context

COVID-19 Reclassified

7,993 studies on the registry are indexed under COVID-19; 468 are open to participants now.

This study's enrollment of 217 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.

Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.

Compared within COVID-19, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Coronavirus Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants of may be enrolled in the study if the participant fulfills all of the following criteria:

    1. Has a negative pregnancy test on the day of injection prior to vaccine dose being administered (Day 1).
    2. Has practiced adequate or has abstained from all activities that could result in pregnancy for at least 28 days prior to Day 1.
    3. Has agreed to continue using an effective contraception through 2 weeks following injection.
    4. Is not currently breastfeeding.

Exclusion criteria

Exclusion Criteria:

  • Has known history of SARS-CoV-2 infection within 3 months prior to enrollment.
  • Currently has symptomatic acute or unstable chronic disease requiring medical or surgical care, to include significant change in therapy or hospitalization for worsening disease, at the discretion of the Investigator.
  • Has a medical, psychiatric, or occupational condition that may pose additional risk as a result of participation, or that could interfere with safety assessments or interpretation of results according to the Investigator's judgment.
  • Reported history of congenital or acquired immunodeficiency (for example, ), condition, asplenia, or recurrent severe infections disease.
  • Has known or suspected allergy or history of anaphylaxis, urticaria, or other significant adverse reaction to the vaccine or its .
  • Receipt of the following:

    1. COVID-19 vaccine within 3 months prior to enrollment
    2. Any other licensed vaccine within 28 days before or 2 weeks after the study injection, with the exception of influenza vaccines, which may be given 14 days before or after receipt of a study vaccine.
    3. Systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for ≥10 milligrams/day of prednisone equivalent) or is anticipating the need for immunosuppressive treatment at any time during participation in the study. Note: Inhaled, nasal, and topical steroids are allowed.
    4. Systemic immunoglobulins or blood products within 3 months prior to Screening or plans for receipt during the study.
  • Has donated ≥450 milliliters of blood products within 28 days prior to Screening or plans to donate blood products during the study.
  • Has participated in an interventional clinical study within 28 days prior to Screening or plans to participate in an interventional clinical trial of an vaccine or drug while participating in this study.

Note: Other inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
217 participants (actual)

Study arms

  • Experimental
    Investigational mRNA-1273.815

    Participants will receive Investigational mRNA-1273.815 by intramuscular injection.

    Biological: Investigational mRNA-1273.815

  • Active comparator
    Licensed Spikevax Vaccine

    Participants will receive a licensed Spikevax vaccine by intramuscular injection.

    Biological: Licensed Spikevax Vaccine

Interventions

  • BiologicalInvestigational mRNA-1273.815

    Sterile solution for injection

  • BiologicalLicensed Spikevax Vaccine

    Commercially available formulation

07

What researchers measure

Primary outcomes

  1. Geometric Mean (GM) Value of Neutralizing Antibodies (nAbs) Against SARS-CoV-2-specific Strain at Day 15

    Antibody values reported as below the lower limit of quantification (LLOQ) were replaced by 0.5 \* LLOQ. Values reported greater than the upper limit of quantification (ULOQ) were replaced by the ULOQ if actual values were not available. LLOQ was 38 arbitrary unit (AU)/milliliter (mL) and ULOQ was 6960 AU/mL. 95% confidence interval (CI) of GM value was calculated based on the t-distribution of the log-transformed values for antibodies, then back transformed to the original scale for presentation.

    Time frame: Day 15

Secondary outcomes

  1. Number of Participants With Serious Adverse Events (SAEs), Adverse Events (AEs) of Special Interest (AESIs), and AEs Leading to Withdrawal From the Study

    An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability/permanent damage, was a congenital anomaly/birth defect, or was an important medical event. AESIs included thrombocytopenia, new onset of or worsening of the protocol specified neurologic diseases, anaphylaxis, and myocarditis/pericarditis. Number of participants with SAEs, AESIs, and AEs leading to discontinuation up to Day 15 are reported in this outcome measure. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

    Time frame: Day 1 through Day 15

  2. Seroresponse Rate of nAb Against the SARS-CoV-2-specific Strain: Percentage of Participants With Seroresponse

    Seroresponse at a participant level was defined as a change from baseline below the LLOQ to equal or above 4 \* LLOQ, or at least a 4-fold rise if baseline was equal to or above the LLOQ. LLOQ was 38 AU/mL.

    Time frame: Day 15

08

Results

Posted May 25, 2025

Participant flow

Participant flow — Overall Study
MilestoneInvestigational mRNA-1273.815Licensed Spikevax Vaccine
Started108109
Received study vaccination106109
Completed105109
Not completed30
Withdrew: Withdrawal by subject30

Outcome measures

PrimaryGeometric Mean (GM) Value of Neutralizing Antibodies (nAbs) Against SARS-CoV-2-specific Strain at Day 15

Antibody values reported as below the lower limit of quantification (LLOQ) were replaced by 0.5 \* LLOQ. Values reported greater than the upper limit of quantification (ULOQ) were replaced by the ULOQ if actual values were not available. LLOQ was 38 arbitrary unit (AU)/milliliter (mL) and ULOQ was 6960 AU/mL. 95% confidence interval (CI) of GM value was calculated based on the t-distribution of the log-transformed values for antibodies, then back transformed to the original scale for presentation.

Time frame:
Day 15
Reported as:
Geometric mean · AU/mL
Geometric Mean (GM) Value of Neutralizing Antibodies (nAbs) Against SARS-CoV-2-specific Strain at Day 15
AU/mLInvestigational mRNA-1273.815Licensed Spikevax Vaccine
Geometric Mean (GM) Value of Neutralizing Antibodies (nAbs) Against SARS-CoV-2-specific Strain at Day 151180.55 (927.67 to 1502.38)1300.25 (1056.39 to 1600.40)
Statistical analysis
  • Investigational mRNA-1273.815 vs Licensed Spikevax Vaccine · Geometric mean ratio (gmr): 0.908 · 95% CI 0.662 to 1.245GMR was a secondary endpoint.
SecondaryNumber of Participants With Serious Adverse Events (SAEs), Adverse Events (AEs) of Special Interest (AESIs), and AEs Leading to Withdrawal From the Study

An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability/permanent damage, was a congenital anomaly/birth defect, or was an important medical event. AESIs included thrombocytopenia, new onset of or worsening of the protocol specified neurologic diseases, anaphylaxis, and myocarditis/pericarditis. Number of participants with SAEs, AESIs, and AEs leading to discontinuation up to Day 15 are reported in this outcome measure. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

Time frame:
Day 1 through Day 15
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs), Adverse Events (AEs) of Special Interest (AESIs), and AEs Leading to Withdrawal From the Study
ParticipantsInvestigational mRNA-1273.815Licensed Spikevax Vaccine
SAEs10
AESIs00
AEs Leading to Withdrawal00
SecondarySeroresponse Rate of nAb Against the SARS-CoV-2-specific Strain: Percentage of Participants With Seroresponse

Seroresponse at a participant level was defined as a change from baseline below the LLOQ to equal or above 4 \* LLOQ, or at least a 4-fold rise if baseline was equal to or above the LLOQ. LLOQ was 38 AU/mL.

Time frame:
Day 15
Reported as:
Number · percentage of participants
Seroresponse Rate of nAb Against the SARS-CoV-2-specific Strain: Percentage of Participants With Seroresponse
percentage of participantsInvestigational mRNA-1273.815Licensed Spikevax Vaccine
Seroresponse Rate of nAb Against the SARS-CoV-2-specific Strain: Percentage of Participants With Seroresponse66.0 (56.0 to 75.1)69.2 (59.4 to 77.9)

Adverse events

Collected over Day 1 through Day 15. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Investigational mRNA-1273.8150/108 (0%)1/106 (0.9%)0/106 (0%)
Licensed Spikevax Vaccine0/109 (0%)0/109 (0%)0/109 (0%)
Most frequent serious events
Most frequent serious events
EventInvestigational mRNA-1273.815Licensed Spikevax Vaccine
Small intestinal obstructionGastrointestinal disorders1/1060/109

Baseline characteristics

Safety Set included all enrolled participants who received study drug.

Age, Continuous
Age, Continuous(years)Investigational mRNA-1273.815Licensed Spikevax VaccineTotal
Mean48.2 ± 16.0946.0 ± 17.4747.1 ± 16.80
Sex: Female, Male
Sex: Female, Male(Participants)Investigational mRNA-1273.815Licensed Spikevax VaccineTotal
Female4852100
Male5857115
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Investigational mRNA-1273.815Licensed Spikevax VaccineTotal
Hispanic or Latino358
Not Hispanic or Latino9385178
Unknown or Not Reported101929
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Investigational mRNA-1273.815Licensed Spikevax VaccineTotal
Race — White8292174
Race — Black or African American112
Race — Asian121022
Race — Native Hawaiian or other Pacific Islander101
Race — Multiple235
Race — Other729
Race — Not reported112
09

Study locations

7 sites
  • Paratus Canberra
    Canberra, Australian Capital Territory 2617, Australia
  • Holdsworth House
    Darlinghurst, New South Wales 2010, Australia
  • Paratus Brisbane
    Brisbane, Queensland 2617, Australia
  • USC Morayfield
    Morayfield, Queensland 4506, Australia
  • University of the Sunshine Coast, South Bank
    South Brisbane, Queensland 4101, Australia
  • Emeritus Melbourne
    Camberwell, Victoria 3124, Australia
  • AusTrials Sunshine Hospital
    Melbourne, Victoria 3021, Australia
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in May 2024, 1 month.

Results were first posted in May 2025, 1 year after primary completion.

Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 1 month is below that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2024
First posted
Apr 9, 2024
StartActual
Apr 8, 2024
Primary completionActual
May 10, 2024
CompletionActual
May 10, 2024
Results first posted
May 25, 2025
Last update
May 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT06354998
Lead sponsor
ModernaTX, Inc.
Responsible party
Sponsor
First posted
Apr 9, 2024
Start date
Apr 8, 2024
Primary completion
May 10, 2024
Completion
May 10, 2024
Results posted
May 25, 2025
Last update
May 25, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion